AZN vs. GSK, HLN, SN, CTEC, HIK, HCM, INDV, GNS, SPI, and ONT
Should you be buying AstraZeneca stock or one of its competitors? The main competitors of AstraZeneca include GSK (GSK), Haleon (HLN), Smith & Nephew (SN), ConvaTec Group (CTEC), Hikma Pharmaceuticals (HIK), HUTCHMED (HCM), Indivior (INDV), Genus (GNS), Spire Healthcare Group (SPI), and Oxford Nanopore Technologies (ONT). These companies are all part of the "medical" sector.
GSK (LON:GSK) and AstraZeneca (LON:AZN) are both large-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, valuation, risk, dividends, institutional ownership, media sentiment, community ranking, analyst recommendations and earnings.
GSK pays an annual dividend of GBX 64 per share and has a dividend yield of 3.9%. AstraZeneca pays an annual dividend of GBX 228 per share and has a dividend yield of 1.9%. GSK pays out 5,333.3% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. AstraZeneca pays out 7,524.8% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. GSK is clearly the better dividend stock, given its higher yield and lower payout ratio.
AstraZeneca has higher revenue and earnings than GSK. GSK is trading at a lower price-to-earnings ratio than AstraZeneca, indicating that it is currently the more affordable of the two stocks.
45.4% of GSK shares are held by institutional investors. Comparatively, 50.8% of AstraZeneca shares are held by institutional investors. 1.7% of GSK shares are held by insiders. Comparatively, 0.2% of AstraZeneca shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
In the previous week, AstraZeneca had 1 more articles in the media than GSK. MarketBeat recorded 5 mentions for AstraZeneca and 4 mentions for GSK. GSK's average media sentiment score of 0.45 beat AstraZeneca's score of -0.02 indicating that AstraZeneca is being referred to more favorably in the news media.
AstraZeneca received 769 more outperform votes than GSK when rated by MarketBeat users. Likewise, 63.61% of users gave AstraZeneca an outperform vote while only 50.21% of users gave GSK an outperform vote.
GSK presently has a consensus price target of GBX 1,630.63, indicating a potential downside of 1.35%. AstraZeneca has a consensus price target of £116.86, indicating a potential downside of 2.52%. Given AstraZeneca's higher possible upside, equities research analysts clearly believe GSK is more favorable than AstraZeneca.
GSK has a net margin of 16.25% compared to GSK's net margin of 13.00%. AstraZeneca's return on equity of 46.38% beat GSK's return on equity.
GSK has a beta of 0.27, indicating that its share price is 73% less volatile than the S&P 500. Comparatively, AstraZeneca has a beta of 0.19, indicating that its share price is 81% less volatile than the S&P 500.
Summary
AstraZeneca beats GSK on 12 of the 20 factors compared between the two stocks.
Get AstraZeneca News Delivered to You Automatically
Sign up to receive the latest news and ratings for AZN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding AZN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
AstraZeneca Competitors List
Related Companies and Tools
